Zentalis Pharmaceuticals Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
106
- Stock Symbol
-
ZNTL
- Investments
-
2
- Share Price
-
$1.70
- (As of Friday Closing)
Zentalis Pharmaceuticals General Information
Description
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Contact Information
Website
www.zentalis.comCorporate Office
- 10275 Science Center Drive
- Suite 200
- San Diego, CA 92121
- United States
Corporate Office
- 10275 Science Center Drive
- Suite 200
- San Diego, CA 92121
- United States
Zentalis Pharmaceuticals Stock Performance
As of 13-Nov-2026, Zentalis Pharmaceuticals’s stock price is $1.70. Its current market cap is $167M with 98.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.70 | $1.68 | $1.28 - $6.95 | $167M | 98.3M | 1.31M | -$1.90 |
Zentalis Pharmaceuticals Financials Summary
As of 30-Sep-2026, Zentalis Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 130,748 | (156,575) | (134,861) | 598,859 |
| Revenue | 0 | 0 | 67,425 | 0 |
| EBITDA | (140,238) | (135,879) | (164,390) | (275,492) |
| Net Income | (141,669) | (137,060) | (165,839) | (292,191) |
| Total Assets | 270,193 | 288,967 | 430,337 | 551,688 |
| Total Debt | 32,442 | 35,704 | 39,577 | 43,150 |
Zentalis Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Zentalis Pharmaceuticals Comparisons
Industry
Financing
Details
Zentalis Pharmaceuticals Competitors (8)
One of Zentalis Pharmaceuticals’s 8 competitors is ORIC Pharmaceuticals, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ORIC Pharmaceuticals | Formerly VC-backed | South San Francisco, CA | ||||
| Prelude Therapeutics | Formerly VC-backed | Wilmington, DE | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Enliven Therapeutics | Formerly VC-backed | Burlingame, CA | ||||
| Lyell Immunopharma | Formerly VC-backed | South San Francisco, CA |
Zentalis Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Zentalis Pharmaceuticals Investments (2)
Zentalis Pharmaceuticals’s most recent deal was a Joint Venture with Zentera Therapeutics. The deal was made on 15-May-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Zentera Therapeutics | 15-May-2020 | Joint Venture | Drug Discovery | ||
| Kalyra Pharmaceuticals | 21-Dec-2017 | Later Stage VC | Drug Discovery |
Zentalis Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.27 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Zentalis Pharmaceuticals Exits (1)
Zentalis Pharmaceuticals’s most recent exit was on 21-Dec-2017 from Kalyra Pharmaceuticals. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Kalyra Pharmaceuticals | 21-Dec-2017 | Completed |
|
Zentalis Pharmaceuticals Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Zentera Therapeutics | Shanghai, China | 2020 | |
| Zeno Management | San Diego, CA | 2018 | |
| Zentalis Eta | New York, NY |
Zentalis Pharmaceuticals FAQs
-
When was Zentalis Pharmaceuticals founded?
Zentalis Pharmaceuticals was founded in 2014.
-
Where is Zentalis Pharmaceuticals headquartered?
Zentalis Pharmaceuticals is headquartered in San Diego, CA.
-
What is the size of Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals has 106 total employees.
-
What industry is Zentalis Pharmaceuticals in?
Zentalis Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Zentalis Pharmaceuticals a private or public company?
Zentalis Pharmaceuticals is a Public company.
-
What is Zentalis Pharmaceuticals’s stock symbol?
The ticker symbol for Zentalis Pharmaceuticals is ZNTL.
-
What is the current stock price of Zentalis Pharmaceuticals?
As of 13-Nov-2026 the stock price of Zentalis Pharmaceuticals is $1.70.
-
What is the current market cap of Zentalis Pharmaceuticals?
The current market capitalization of Zentalis Pharmaceuticals is $167M.
-
Who are Zentalis Pharmaceuticals’s competitors?
ORIC Pharmaceuticals, Prelude Therapeutics, Ayala Pharmaceuticals, Enliven Therapeutics, and Lyell Immunopharma are some of the 8 competitors of Zentalis Pharmaceuticals.
-
What is Zentalis Pharmaceuticals’s annual earnings per share (EPS)?
Zentalis Pharmaceuticals’s EPS for 12 months was -$1.90.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
